

Ovarian Cancer: Effective Practices to Benefit Patients

- In advanced ovarian cancer, genetic testing rates hover around 50%.¹
- Only 49% of patients received maintenance therapy in second line or greater therapy.²
- Current rates warrant improved methods and practices to enable professionals to both identify and offer PARP-Inhibitors to appropriate patients at the right time.
 - **NCODA's Positive Quality Intervention (PQI)** on this topic provides practical guidance and is available here: www.ncoda.org/ovarian-cancer-parp-inhibitor-eligibility

This EMR Resource provides simple step-by-step instructions to:

 **1. Run a Report:** to search for all ovarian cancer patients

 **2. Review Chart:** to conduct a clinical assessment

 **3. Create Reminders and Track:** key treatment milestones and timing of therapy

1. Run a Report

From the vertical toolbar on the left side of the home screen, select **Reports**

Select Patient Staging Analysis (Cancer Diagnosis)

Select MDs

Select Locations

Select Dates


Select Disease (ovarian)

Choose Primary and Secondary diagnoses

To identify all ovarian cancer patients within the EMR, search by "Ovarian"


2. Review Chart

From the patient list, select a patient and review each patient case to determine



3. Create Reminders and Track

For each patient, create a tracking system and reminder flag via “Activity” function



1. Randall LM, Aydin E, Louie-Gao M, Hazard S, Westin SN. A retrospective analysis of real-world tumor BRCA (tBRCA) testing trends in ovarian cancer before and after PARP inhibitor approvals. Presented at the 17th Biennial Meeting of the International Gynecologic Cancer Society; Kyoto, Japan: 2018.
 2. Garofalo D, Verma-Kurvari S, Aydin E, et al. Real world data analysis of ovarian cancer maintenance utilization among maintenance eligible patients. Presented at the American Society of Clinical Oncology Annual Congress; Chicago, IL: 2019.